Cystoid macular edema in uveitis

References

• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–336.
   PubMed Web of Science ®Google Scholar
• Atmaca LS. Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol. 1989;227:340–344.
   PubMed Web of Science ®Google Scholar
• Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001;9:93–102.
   PubMed Web of Science ®Google Scholar
• Henderly DE, Genstler AJ, Rao NA, Smith RE. Pars planitis. Trans Ophthalmol Soc UK. 1986;105:227–232.
   Google Scholar
• Henderly DE, Haymond RS, Rao NA, Smith RE. The significance of the pars plana exudate in pars planitis. Am J Ophthalmol. 1987;103: 669–671.
   PubMed Web of Science ®Google Scholar
• Yanoff M, Fine BS, Brucker AJ, Eagle Jr RC. Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28(Suppl):505-5 H.
   Google Scholar
• Hirokawa H, Takahashi M, Trempe CL. Vitreous changes in peripheral uveitis. Arch Ophthalmol. 1985;103: 1704–1707.
   Google Scholar
• Hikichi T, Trempe CL. Role of the vitreous in the prognosis of peripheral uveitis. Am J Ophthalmol. 1993;1 16:401–405.
   Google Scholar
• Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4:1–5.
   PubMed Web of Science ®Google Scholar
• Lightman S, Chan CC. Immune mechanisms in choroido-retinal inflammation in man. Eye. 1990;4: 345–353.
   PubMedGoogle Scholar
• Lightman S, Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Gun Exp Immunol. 1992;88:473–477.
   PubMed Web of Science ®Google Scholar
• Lightman SL, Caspers-Velu LE, Hirose S, Nussenblatt RB, Palestine AG. Angiography with fluorescein-labeled dextrans in a primate model of uveitis. Arch Ophthalmol. 1987; 105:844–848.
   PubMedGoogle Scholar
• Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97:297–309.
   PubMed Web of Science ®Google Scholar
• Lightman S. Use of steroids and immunosuppressive drugs in the management of posterior uveitis. Eye. 1991;5:294–298.
   PubMedGoogle Scholar
• Nussenblatt RB, Kaufman SC, Palestine AG, Davis MD, Ferris 3rd FL. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology. 1987;94:1134–1139.
   Google Scholar
• McCluskey PJ, Towler HM, Lightman S. Management of chronicuveitis. Br Med J. 2000;320:555–558.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.
   Google Scholar
• Rojas B, Zafirakis P, Christen W, Markomichelakis NN, Foster CS. Medical treatment of macular edema in patients with uveitis. Doc Ophthalmol. 1999;97:399–407.
   Google Scholar
• Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Gun Exp Ophthalmol. 2001;29:2–6.
   PubMed Web of Science ®Google Scholar
• Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999; 106:370–374.
   Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S, Sahin 0, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002; 109:370–377.
   Google Scholar
• Herbort CP, Okumura A, Mochizuki M. Immunopharmacological analysis of endotoxin-induced uveitis in the rat. Exp Eye Res. 1989;48:693–705.
   Google Scholar
• Mishima H, Masuda K, Miyake K. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res. 1989;312:251–264.
   Google Scholar
• Goa KL, Chrisp P. Ocular diclofenac. A review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions. Drugs Aging. 1992;2:473–486.
   Google Scholar
• Dugel PU, Rao NA, Ozler S, Liggett PE, Smith RE. Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study. Ophthalmology. 1992;99:1535–1541.
   Google Scholar
• Aylward GW. The place of vitreoretinal surgery in the treatment of macular oedema. Doc Ophthalmol. 1999;97:433–438.
   PubMedGoogle Scholar
• Verbraeken H. Pars plana lensectomy in cases of cataract with juvenile chronic uveitis. Graefes Arch Clin Exp Ophthalmol. 1996; 234:618–622.
   Google Scholar
• Okhravi N, Towler HM, Lightman SL. Cataract surgery in patients with uveitis. Eye. 2000;14(5):689–690.
   Google Scholar
• Smith JR. Management of uveitis in pediatric patients: special considerations. Paediatr Drugs. 2002; 4:183–189.
   Google Scholar
• Guest S, Funkhouser E, Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin Exp Ophthalmol. 2001;29:81–84.
   Google Scholar
• Karavellas MP, Azen SP, MacDonald JC, Shufelt CL, Lowder CY, Plummer DJ, Glasgow B, Torriani FJ, Freeman WR. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequlae, and treatment outcomes. Retina. 2001;21:1–9.
   Google Scholar
• Lightman S, Kok H. Developments in the treatment of uveitis. Expert Opin Invest Drugs. 2002;11:59–67.
   PubMed Web of Science ®Google Scholar
• Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol. 1995;23:293–298.
   PubMed Web of Science ®Google Scholar
• Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Exp Ophthalmol. 2001;29:188–192.
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Pearson PA, Ashton P, Jaffe GI An intravitreal device providing sustained release of cyclosporine and dexamethasone. Curr Eye Res. 1996;15:549–557.
   PubMed Web of Science ®Google Scholar
• Jaffe GI Yang CS, Wangm XC, Cousins W, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998;105:46–56.
   Google Scholar
• Jaffe GI Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033.
   Google Scholar
• Jaffe GI Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20: 402–403.
   Google Scholar
• Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis- associated cystoid macular edema. Am J Ophthalmol. 2001;132:794–796.
   Google Scholar
• Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:148o–148T
   Google Scholar